Bayesian AI Platform Leverage BPGbio's proprietary NAi Bayesian AI platform to accelerate target discovery, mechanism insight, and biomarker development across oncology, rare disease, and neurology. Propose collaboration, co-development, or licensing arrangements to shorten preclinical timelines for pharma partners.

Data Asset Licensing Access to the world's largest clinically annotated non-governmental biobank with longitudinal samples creates a unique data asset for patient stratification, real-world evidence, and comparator datasets. Explore data licensing, data-sharing collaborations, and sponsored studies with pharma and CROs.

Compute Advantage Exclusive access to a powerful supercomputer enables large-scale biology simulations and rapid hypothesis testing. Offer HPC-backed discovery services and joint data-intensive programs to biopharma partners.

Strategic Leadership Recent leadership appointments demonstrate execution readiness and deep scientific networks. Leverage these relationships to structure advisory boards, co-development deals, and targeted outreach to opportunities in BPGbio's focus areas.

Therapeutic Focus Mitochondrial biology and protein homeostasis underpin a late-stage oncology, rare disease, and neurology pipeline. Target partners seeking mitochondrial or proteostasis targets for co-development, licensing, or collaboration that can leverage AI and data assets to derisk programs.